Recent News

• 03.26.2025 - Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
• 03.26.2025 - Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
• 03.25.2025 - Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
• 03.25.2025 - Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
• 03.12.2025 - 2025 Leerink Partners Global Healthcare Conference
• 03.12.2025 - 2025 Leerink Partners Global Healthcare Conference
• 03.11.2025 - Barclays 27th Annual Global Healthcare Conference
• 03.11.2025 - Barclays 27th Annual Global Healthcare Conference
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference

Recent Filings

• 03.05.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 144 Report of proposed sale of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities